Brief: Imfinzi approved in US as first immunotherapy combo for high‑risk bladder cancer
28/05/2026 20:31
BRIEF-Imfinzi approved in US as first immunotherapy combo for high‑risk bladder cancer May 28 (Reuters) - AstraZeneca PLC AZN.L:
IMFINZI APPROVED IN THE US IN FIRST AND ONLY IMMUNOTHERAPY COMBINATION FOR PATIENTS WITH BCG-NAÏVE, HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER.
Source text: ID:nPLX3TMKQS
Further company coverage: AZN.L
((((Reuters.Briefs@thomsonreuters.com));))
Recent news on AstraZeneca
See all newsUK Stocks-Factors to watch on July 10 (updated)
UK Stocks-Factors to watch on July 10
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight (updated)
US appeals court upholds win for AstraZeneca in Pfizer cancer drug patent fight
UK's FTSE 100 ticks lower as AstraZeneca drag offsets banks, mining gains